Repligen | RGEN - Operating Profit


Repligen reported $12.68M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agilent USD 443M 66M Sep/2025
Align Technology USD 184.65M 21.61M Sep/2025
Bio Techne USD 54.46M 6.8M Dec/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Bruker USD 83.9M 72M Sep/2025
Charles River Laboratories USD 133.8M 1.46M Sep/2025
Danaher USD 1.5B 348M Dec/2025
Dentsply International USD 512M 401M Sep/2025
Exact Sciences USD -25M 22.85M Sep/2025
General Electric Aerospace USD 1.77B 536M Dec/2025
Henry Schein USD 198M 22M Sep/2025
Illumina USD 250M 5M Sep/2025
IQVIA Holdings USD 573M 17M Sep/2025
Mettler Toledo International USD 294.2M 28.49M Sep/2025
Myriad Genetics USD -23.3M 10.8M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Repligen USD 12.68M 6.72M Sep/2025
Revvity USD 98.34M 8.63M Sep/2025
Standard Biotools USD -23.47M 230K Sep/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Waters USD 192.11M 3.9M Sep/2025
West Pharmaceutical Services USD 167.6M 13.9M Sep/2025